Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$25.03B
Positions
121
New
14
Increased
16
Decreased
64
Sold Out
8
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $25.03B across 121 positions in their Q3 2020 SEC 13F filing (period ending 2020-09-30). The top 10 positions account for 85.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENUSDSeagen Inc. | $9.25B | 36.96% | New |
| 2 | ONCBeiGene, Ltd. | $3.81B | 15.22% | +12.9% |
| 3 | INCYIncyte Corporation | $2.87B | 11.47% | +0.0% |
| 4 | ACADACADIA Pharmaceuticals Inc. | $1.73B | 6.91% | - |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | $1.00B | 4.01% | - |
| 6 | KODKodiak Sciences Inc. | $731.37M | 2.92% | +6.7% |
| 7 | BMRNBioMarin Pharmaceutical Inc. | $577.39M | 2.31% | - |
| 8 | ASNDUSDAscendis Pharma A/S | $546.33M | 2.18% | +4.4% |
| 9 | NVTA1EURInvitae Corporation | $513.74M | 2.05% | - |
| 10 | MYOKEURMyoKardia, Inc. | $410.26M | 1.64% | -4.9% |
| Stock | Value | Shares |
|---|---|---|
| SGENUSDSeagen Inc. | $9.25B | 47,269,424 |
| PRLDPrelude Therapeutics Incorporated | $304.88M | 10,118,636 |
| KYMRKymera Therapeutics, Inc. | $63.30M | 1,959,211 |
| NRIXNurix Therapeutics, Inc. | $62.45M | 1,788,921 |
| PACBPacific Biosciences of California, Inc. | $32.08M | 3,250,000 |
| NVTA 2 09/01/24Invitae Corporation | $16.91M | 10,300,000 |
| ATHAAthira Pharma, Inc. | $16.29M | 882,352 |
| HRMYHarmony Biosciences Holdings, Inc. | $13.56M | 400,000 |
| IMTXImmatics N.V. | $10.63M | 1,001,414 |
| 5E7Iteos Therapeutics, Inc. | $4.13M | 167,562 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.